The management of orthostatic hypotension in Parkinson's disease. [artículo]
Por: Benito León, Julián [Neurología] | Sánchez Ferro, Álvaro [Neurología].
Colaborador(es): Servicio de Neurología-Neurofisiología.
Editor: Frontiers in neurology, 2013Descripción: 4:64.Recursos en línea: Acceso libre Resumen: Orthostatic hypotension (OH) is a common and disabling symptom affecting Parkinson's disease (PD) patients. We present the effect of the different therapies commonly used to manage PD on this clinical manifestation. For this purpose, we describe the relationship between OH and the current treatments employed in PD, such as L-DOPA, dopaminergic agonists, and continuous dopaminergic stimulation therapies. Additionally, we review the therapeutic measures that could be used to ameliorate OH. There are different approaches to deal with this manifestation, including pharmacological and non-pharmacological treatments, although none of them is specifically aimed for treating OH in PD.Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
---|---|---|---|---|
Artículo | PC1515 (Navegar estantería) | Disponible |
Navegando Hospital Universitario 12 de Octubre Estantes Cerrar el navegador de estanterías
PC15147 Crisis de asma | PC15148 Urticaria. Angioedema. Shock anafiláctico | PC15149 Tos: diagnóstico diferencial | PC1515 The management of orthostatic hypotension in Parkinson's disease. | PC15150 Fibrosis quística | PC15151 Ataxia y vértigo | PC15152 Cefaleas |
Formato Vancouver:
Sánchez-Ferro A, Benito-León J, Gómez-Esteban JC. The management of orthostatic hypotension in Parkinson's disease. Front Neurol. 2013 Jun 10;4:64.
PMID: 23772219
Contiene 149 referencias
Orthostatic hypotension (OH) is a common and disabling symptom affecting Parkinson's disease (PD) patients. We present the effect of the different therapies commonly used to manage PD on this clinical manifestation. For this purpose, we describe the relationship between OH and the current treatments employed in PD, such as L-DOPA, dopaminergic agonists, and continuous dopaminergic stimulation therapies. Additionally, we review the therapeutic measures that could be used to ameliorate OH. There are different approaches to deal with this manifestation, including pharmacological and non-pharmacological treatments, although none of them is specifically aimed for treating OH in PD.
No hay comentarios para este ejemplar.